Allovate Therapeutics is a specialty biopharmaceutical company dedicated to simplifying allergy treatment by providing safe, effective, and convenient new options for allergy sufferers. Oral mucosal immunotherapy (OMIT) is a novel form of allergen-specific immunotherapy. Immunotherapy has a 100-year track record of success for respiratory allergies. OMIT improves upon this approach by delivering immunotherapeutic agents to the areas of the oral cavity with the highest likelihood of prompting a decrease in allergy symptoms in order to improve the health of allergy sufferers. Clinical investigations led by Allovate are developing the OMIT platform for the treatment of respiratory allergies to environmental substances like dust mite, pollen, animal dander, and molds. OMIT offers the potential of a long-term solution for more than 60 million Americans and more than 200 million people worldwide who have allergies.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Nationally (across the country)
- Year Founded:
Allovate Therapeutics is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. During this global COVID-19 pandemic, many allergy patients are required to stay at home, reducing their ability to visit physicians. Allerdent® is an option that enables patients to maintain allergy immunotherapy while staying home during the COVID-19 pandemic. Upon request, we are making free supplies of our Allerdent® product available for physicians who need to provide treatment to patients required to stay at home this May and June.